Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, “Our study suggests that besides obesity and diabetes, GLP-1-agonists may also help in the treatment of alcohol and substance use disorders; however, these findings need to be further validated in randomized controlled trials.”

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart disease, Parkinson’s, sleep apnea and addiction.

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and osteoarthritis.

The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require hospitalization, new research shows. Numerous studies had already hinted that semaglutide might act on appetite centers in the brain to suppress the urge to drink,

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests.

Ozempic, a diabetes drug that has become a popular drug for weight loss, has another use that could help tens of millions of Americans, researchers say. In a study published in the journal JAMA Psychiatry,